Reuters logo
BRIEF-ProQR announces positive top-line results from a phase 1b study of QR-010
September 25, 2017 / 8:07 PM / a month ago

BRIEF-ProQR announces positive top-line results from a phase 1b study of QR-010

Sept 25 (Reuters) - ProQR Therapeutics NV

* ProQR announces positive top-line results from a Phase 1b study of QR-010 in subjects with Cystic Fibrosis

* ProQR Therapeutics - ‍QR-010 observed to be safe and well-tolerated across all doses in the trial with no serious adverse events related to treatment​

* ProQR Therapeutics NV - Co, Cystic Fibrosis Foundation Therapeutics intend to expand their partnership to explore inhaled Oligonucleotide platform Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below